1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Brain Tumor Report is to understand the market and pipeline status of the drugs around the Brain Tumor to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Brain Tumor. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Brain Tumor.
- A review of the marketed products under prescription for Brain Tumor, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Brain Tumor with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Brain Tumor drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Brain Tumor drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Brain Tumor drugs.
- Coverage of Brain Tumor Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Brain Tumor key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Brain Tumor.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Brain Tumor.
- API intelligence over marketed drugs forBrain Tumorand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Brain Tumor.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Brain Tumor
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Brain Tumor
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Brain Tumor
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Brain Tumor Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Brain Tumor Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Brain Tumor Therapeutic Market, US, (Year), 2016
- Brain Tumor Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Brain Tumor Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Brain Tumor Drugs, API Manufacturers, Europe by Country, 2016
- Brain Tumor Drugs, API Manufacturers, India by State, 2016
- Brain Tumor Drugs, API Manufacturers, China by Province, 2016
- Brain Tumor Drugs, API Manufacturers by Geography 2016
- Brain Tumor Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Brain Tumor Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Brain Tumor, 2016
- Discontinued Drugs for Brain Tumor, 2016

List of Figures

- Brain Tumor Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Brain Tumor Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Brain Tumor Therapeutic Market, US, (Year), 2016
- Brain Tumor Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Brain Tumor Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Brain Tumor Drugs, API Manufacturers, Europe by Country, 2016
- Brain Tumor Drugs, API Manufacturers, India by State, 2016
- Brain Tumor Drugs, API Manufacturers, China by Province, 2016
- Brain Tumor Drugs, API Manufacturers by Geography 2016
- Brain Tumor Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Brain Tumor Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Brain Cancer: Analytical Tool

Brain Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics and Therapy Market in the US - Forecast

  • November 2016
    52 pages
  • Cancer  

    Therapy  

  • United States  

View report >

Related Market Segments :

Brain Cancer
Cloud Computing

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.